Axsome Therapeutics, Inc. , a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today announced that the Company has entered into a. | March 28, 2022
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with. | March 28, 2022
DUBLIN, March 1, 2022 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provided financial guidance for
/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provided financial.